Buckingham Capital Management Inc. reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,290 shares of the medical equipment provider’s stock after selling 40 shares during the quarter. Buckingham Capital Management Inc.’s holdings in Zimmer Biomet Holdings were worth $294,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Bronfman E.L. Rothschild L.P. raised its stake in Zimmer Biomet Holdings by 25.3% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 167 shares during the period. Parkside Financial Bank & Trust raised its stake in Zimmer Biomet Holdings by 2.7% during the 1st quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 22 shares during the period. Parallel Advisors LLC raised its stake in Zimmer Biomet Holdings by 20.8% during the 1st quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after purchasing an additional 199 shares during the period. IHT Wealth Management LLC raised its stake in Zimmer Biomet Holdings by 28.4% during the 1st quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after purchasing an additional 256 shares during the period. Finally, Sandy Spring Bank raised its stake in Zimmer Biomet Holdings by 1.7% during the 1st quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock valued at $149,000 after purchasing an additional 20 shares during the period. 85.48% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/09/13/zimmer-biomet-holdings-inc-zbh-holdings-cut-by-buckingham-capital-management-inc.html.

Zimmer Biomet Holdings, Inc. (ZBH) traded down 0.33% during trading on Wednesday, reaching $116.05. 179,829 shares of the company’s stock traded hands. The firm has a 50 day moving average price of $116.25 and a 200-day moving average price of $120.83. Zimmer Biomet Holdings, Inc. has a 12 month low of $95.63 and a 12 month high of $133.49. The firm has a market cap of $23.46 billion, a PE ratio of 33.05 and a beta of 1.21.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the consensus estimate of $2.10 by ($0.02). The firm had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The firm’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.02 earnings per share. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 annualized dividend and a dividend yield of 0.82%. Zimmer Biomet Holdings’s dividend payout ratio is presently 27.59%.

Several brokerages have issued reports on ZBH. Morgan Stanley boosted their target price on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a research note on Monday, July 17th. Stifel Nicolaus reissued a “hold” rating and set a $125.00 target price on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Piper Jaffray Companies reissued a “buy” rating and set a $141.00 target price on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Wells Fargo & Company reissued a “market weight” rating on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $140.00 target price on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $136.75.

In other news, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 1.07% of the stock is owned by insiders.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.